Chronic lymphocytic leukemia prognostic models in real life: still a long way off

References

• Wierda WG, O’Brien S, Wang X, et al. Prognostic nomogram and index for overall survival in previously untreated patients with chronic lymphocytic leukemia. Blood. 2007;109(11):4679–4685.
   PubMed Web of Science ®Google Scholar
• Rossi D, Spina V, Bomben R, et al. Integrated mutational and cytogenetic analysis identifies new prognostic subgroups in chronic lymphocytic leukemia. Blood. 2013;121(8):1403–1412.
   PubMed Web of Science ®Google Scholar
• Pflug N, Bahlo J, Shanafelt TD, et al. Development of a comprehensive prognostic index for patients with chronic lymphocytic leukemia. Blood. 2014;124(1):49–62.
   PubMed Web of Science ®Google Scholar
• International CLL-IPI working group. An international prognostic index for patients with chronic lymphocytic leukaemia (CLL-IPI): a meta-analysis of individual patient data. Lancet Oncol. 2016;17(6):779–790.
   PubMed Web of Science ®Google Scholar
• Delgado J, Doubek M, Baumann T, et al. Chronic lymphocytic leukemia: a prognostic model comprising only two biomarkers (IGHV mutational status and FISH cytogenetics) separates patients with different outcome and simplifies the CLL-IPI. Am J Hematol. 2017;92(4):375–380.
   PubMed Web of Science ®Google Scholar
• Kreuzberger N, Damen JA, Trivella M, et al. Prognostic models for newly-diagnosed chronic lymphocytic leukaemia in adults: a systematic review and meta-analysis. Cochrane Database Syst Rev. 2020 Jul 31;7:CD012022.
   PubMedGoogle Scholar
• Soumerai JD, Ni A, Darif M, et al. Prognostic risk score for patients with relapsed or refractory chronic lymphocytic leukaemia treated with targeted therapies or chemoimmunotherapy: a retrospective, pooled cohort study with external validations. Lancet Haematol. 2019 Jul;6(7):e366–e374.
   PubMed Web of Science ®Google Scholar
• Alba AC, Agoritsas T, Walsh M, et al. Discrimination and Calibration of Clinical PredictionModels Users’ Guides to the Medical Literature. JAMA. 2017 Oct 10;318(14):1377–1384.
   PubMed Web of Science ®Google Scholar
• Montserrat E, Gale RP. Predicting the outcome of patients with chronic lymphocytic leukemia: progress and uncertainty. Cancer. 2019Nov1;125(21):3699–3705.
   PubMed Web of Science ®Google Scholar
• Molica S, Giannarelli D. Prognostic models for chronic lymphocytic leukemia (CLL): a systematic review and meta-analysis. Leukemia. 2020 Jun 21. DOI:10.1038/s41375-020-0924-8..
   PubMedGoogle Scholar
• Gordon MJ, Churnetski M, Alqahtani H, et al. Comorbidities predict inferior outcomes in chronic lymphocytic leukemia treated with ibrutinib. Cancer. 2018;124:3192–3200.
   PubMed Web of Science ®Google Scholar
• Rigolin GM, Cavallari M, Quaglia FM, et al. In CLL, comorbidities and the complex karyotype are associated with an inferior outcome independently of CLL-IPI. Blood. 2017;129:3495–3498.
   PubMed Web of Science ®Google Scholar
• Condoluci A, Terzi Di Bergamo L, Langerbeins P, et al. International prognostic score for asymptomatic early-stage chronic lymphocytic leukemia. Blood. 2020 May 21;135(21):1859–1869.
   PubMed Web of Science ®Google Scholar
• Gentile M, Shanafelt TD, Rossi D, et al. Validation of the CLL IPI and comparison with the MDACC prognostic index in newly diagnosed patients. Blood. 2016;128(16):2093–2095.
   PubMed Web of Science ®Google Scholar
• Zhu HY, Wang L, Qiao J, et al. Prognostic significance of CLL-IPI for Chinese patients with chronic lymphocytic leukemia. Zhonghua Xue Ye Xue Za Zhi. 2018 May 14;39(5):392–397.
   PubMedGoogle Scholar
• Rani L, Gogia A, Singh V, et al. Comparative assessment of prognostic models in chronic lymphocytic leukemia: evaluation in Indian cohort. Ann Hematol. 2019 Feb;98(2):437–443.
   PubMed Web of Science ®Google Scholar
• Muñoz-Novas C, Poza-Santaella M, González-Gascón Y, et al. The International Prognostic Index for patients with Chronic Lymphocytic Leukemia has the higher value in predicting overall outcome compared with the Barcelona-Brno biomarkers only prognostic model and the MD Anderson Cancer Center prognostic Index. Biomed Res Int. 2018;2018:9506979.
   PubMed Web of Science ®Google Scholar
• Bulian P, Tarnani M, Rossi D, et al. Multicentre validation of a prognostic index for overall survival in chronic lymphocytic leukaemia. Hematol Oncol. 2011;29(2):91–99.
   PubMed Web of Science ®Google Scholar
• Gentile M, Mauro FR, Rossi D, et al. Italian external and multicentric validation of the MDAnderson Cancer Center nomogram and prognostic index for chronic lymphocytic leukaemia patients: analysis of 1502 cases. Br J Haematol. 2014;167:224–232.
   PubMed Web of Science ®Google Scholar
• Gonzalez Rodriguez AP, Gonzalez Garcia E, Fernandez, et al. B-chronic lymphocytic leukemia: epidemiological study and comparison of MDACC and GIMENA pronostic indexes [Estudio epidemiológico y comparación de los índices pronósticos del MD Anderson Cancer Center y el índice del Gruppo Italiano Malattie Ematologiche Maligne dell’ Adulto en pacientes con leucemia linfática crónica de células B]. Med Clin. 2009;133(5):161–166.
   PubMedGoogle Scholar
• Shanafelt TD, Jenkins G, Call TG, et al. Validation of a new prognostic index for patients with chronic lymphocytic leukemia. Cancer. 2009;115:363–372.
   PubMed Web of Science ®Google Scholar
• Gentile M, Shanafelt TD, Mauro FR, et al. Comparison between the CLL-IPI and the Barcelona-Brno prognostic model: analysis of 1299 newly diagnosed cases. Am J Hematol. 2017;93(2):E35–7.
   PubMed Web of Science ®Google Scholar
• Molica S. Progression and survival studies in early chronic lymphocytic leukemia. Blood. 1991;78(4):895–899.
   PubMed Web of Science ®Google Scholar
• Herling CD, Cymbalista F, Groß-Ophoff-Müller C, et al. Early treatment with FCR versus watch and wait in patients with stage Binet A high-risk chronic lymphocytic leukemia (CLL): a randomized phase 3 trial. Leukemia. 2020 Aug;34(8):2038–2050. Epub 2020 Feb 18.
   PubMed Web of Science ®Google Scholar
• Langerbeins P, Bahlo J, Rhein C, et al. Ibrutinib versus placebo in patients with asymptomatic, treatment-naïve early stage CLL: primary endpoint results of the phase 3 double-blind randomized CLL12 trial. Hematol Oncol. 2019;37(S2):38–40.
   PubMedGoogle Scholar
• Hallek M, Cheson BD, Catovsky D, et al. International workshop on chronic lymphocytic leukemia. Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the international workshop on chronic lymphocytic leukemia updating the national cancer institute-working group 1996 guidelines. Blood. 2008;111(12):5446–5456.
   PubMed Web of Science ®Google Scholar
• Wierda WG, O’Brien S, Wang X, et al. Multivariable model for time to first treatment in patients with chronic lymphocytic leukemia. J Clin Oncol. 2011;29(31):4088–4095.
   PubMed Web of Science ®Google Scholar
• Molica S, Giannarelli D, Gentile M, et al. External validation on a prospective basis of a nomogram for predicting the time to first treatment in patients with chronic lymphocytic leukemia. Cancer. 2013;119(6):1177–1185.
   PubMed Web of Science ®Google Scholar
• Molica S, Shanafelt TD, Giannarelli D, et al. The chronic lymphocytic leukemia international prognostic index predicts time to first treatment in early CLL: independent validation in a prospective cohort of early stage patients. Am J Hematol. 2016 Nov;91(11):1090–1095.
   PubMed Web of Science ®Google Scholar
• Gentile M, Shanafelt TD, Cutrona G, et al. A progression-risk score to predict treatment-free survival for early stage chronic lymphocytic leukemia patients. Leukemia. 2016;6(30):1440–1443.
   PubMed Web of Science ®Google Scholar
• González-Gascón-Y-Marín I, Muñoz-Novas C, Figueroa I, et al. Prognosis assessment of early-stage chronic lymphocytic leukemia: are we ready to predict clinical evolution without a crystal ball? Clin Lymphoma Myeloma Leuk. 2020 Aug;20(8):548–555.
   PubMed Web of Science ®Google Scholar
• Munir T, Brown JR, O’Brien S, et al. Final analysis from RESONATE: up to six years of follow-up on ibrutinib in patients with previously treated chronic lymphocytic leukemia or small lymphocytic lymphoma. Am J Hematol. 2019 Dec;94(12):1353–1363.
   PubMed Web of Science ®Google Scholar
• Molica S, Baumann TS, Lentini M, et al. The BALL prognostic score identifies relapsed/refractory CLL patients who benefit the most from single-agent ibrutinib therapy. Leuk Res. 2020 Aug 95;95:106401. Epub 2020 Jun 10.
   PubMed Web of Science ®Google Scholar
• Gentile M, Morabito F, Del Poeta G, et al. Survival risk score for real-life relapsed/refractory chronic lymphocytic leukemia patients receiving ibrutinib. A campus CLL study. Leukemia. 2020 Apr 14. DOI:10.1038/s41375-020-0833-x.. [ Online ahead of print].
   Google Scholar
• Ahn IE, Tian X, Ipe D, et al. Prediction of outcome in patients with chronic lymphocytic leukemia treated with ibrutinib: development and validation of a four-factor prognostic model. J Clin Oncol. 2020 Oct 7:JCO2000979. Online ahead of print. DOI:10.1200/JCO.20.00979.
   PubMed Web of Science ®Google Scholar
• Letestu R, Dahmani A, Boubaya M, et al. Prognostic value of high-sensitivity measurable residual disease assessment after front-line chemoimmunotherapy in chronic lymphocytic leukemia. Leukemia. 2020 Sep 15. DOI:10.1038/s41375-020-01009-z..
   Web of Science ®Google Scholar
• Gopalakrishnan S, Wierda W, Chyla B, et al. Integrated mechanistic model of minimal residual disease kinetics with venetoclax therapy in chronic lymphocytic leukemia. Clin Pharmacol Ther. 2020 Aug 4. 10.1002/cpt.2005.. [ Online ahead of print].
   Web of Science ®Google Scholar
• Fürstenau M, De Silva N, Eichhorst B, et al. Minimal residual disease assessment in CLL: ready for use in clinical routine? Hemasphere. 2019 Aug 9;3(5):e287. eCollection. 2019 Oct.
   PubMed Web of Science ®Google Scholar
• Molica S, Giannarelli D, Montserrat E. Minimal residual disease and survival outcomes in patients with chronic lymphocytic leukemia: a systematic review and meta-analysis. Clin Lymphoma Myeloma Leuk. 2019;19(7):423–430.
   PubMed Web of Science ®Google Scholar
• Kurtz DM, Esfahani MS, Scherer F, et al. Dynamic risk profiling using serial tumor biomarkers for personalized outcome prediction. Cell. 2019 Jul 25;178(3):699–713. e19
   PubMed Web of Science ®Google Scholar
• Woyach JA, Ruppert AS, Guinn D, et al. BTK C481S-mediated resistance to Ibrutinib in chronic lymphocytic leukemia. J Clin Oncol. 2017 May 1;35(13):1437–1443.
   PubMed Web of Science ®Google Scholar
• Blombery P, Anderson MA, Gong JN, et al. Acquisition of the recurrent Gly101Val mutation in BCL2 confers resistance to venetoclax in patients with progressive chronic lymphocytic leukemia. Cancer Discov. 2019;9(3):342–353.
   PubMed Web of Science ®Google Scholar
• Baliakas P, Moysiadis T, Hadzidimitriou A, et al. Tailored approaches grounded on immunogenetic features for refined prognostication in chronic lymphocytic leukemia. Haematologica. 2019;104:360–369.
   PubMed Web of Science ®Google Scholar
• Zia O, Emanuel EJ. Predicting the future - big data, machine learning, and clinical medicine. N Engl J Med. 2016 Sep 29;375(13):1216–1219.
   PubMed Web of Science ®Google Scholar
• Agius R, Brieghel C, Andersen MA, et al. Machine learning can identify newly diagnosed patients with CLL at high risk of infection. Nat Commun. 2020 Jan 17;11(1):363.
   PubMed Web of Science ®Google Scholar